Xiaoqing Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaoqing Wang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Guang Zhao
Department of Neurology, Changhai Hospital, Second Military Medical University, Shanghai, China
1 shared publication- Jianming Jiang
Department of Neurology, Changhai Hospital, Second Military Medical University, Shanghai, China
1 shared publication Xiaowen Yu
Department of Neurology, Changhai Hospital, Second Military Medical University, Shanghai, China
1 shared publicationXiutian Zhang
Department of Neurology, Changhai Hospital, Second Military Medical University, Shanghai, China
1 shared publication- Yangtai Guan
Department of Neurology, Punan Branch of Renji Hospital, Shanghai Jiao Tong University School of Medicine (Punan Hospital in Pudong new district), Shanghai, China
1 shared publication
Latest Publications
- 1 January 2017
- Published by Edikta s.r.l. in Bone Abstracts
- Vol. 14 (2) , 247-249
Primary central nervous system germinal center B-like diffuse large B-cell lymphoma: a case report
We report a case of a 54-year-old HIV-negative female who presented with a 2-month history of ongoing post meridiem low-level fever and new onset progressive paralysis. On MRI (magnetic resonance imaging), an infiltrative enhancing lesion was noted, which initially resembled that of MS, but she reacted not sensitively with immunosuppressive therapy, we performed a brain biopsy to her, it turned out to be primary CNS (central nervous system) diffuse large B-cell lymphoma (DLBCL). And the morphology, the flow cytometric findings were consistent with germinal center B-like diffuse large B-cell lymphoma. There were only a few case reports concerning primary CNS DLBCL of GCB. The misdiagnose of this patient should alarm the bell, and we should consider biopsy when the lesion is near the cortex in the brain. Why she reacted not sensitively with immunosuppressive therapy later is analyzed.
- 1 January 2017
- Published by Edikta s.r.l. in Bone Abstracts
- Vol. 14 (2) , 247-249
Primary central nervous system germinal center B-like diffuse large B-cell lymphoma: a case report
We report a case of a 54-year-old HIV-negative female who presented with a 2-month history of ongoing post meridiem low-level fever and new onset progressive paralysis. On MRI (magnetic resonance imaging), an infiltrative enhancing lesion was noted, which initially resembled that of MS, but she reacted not sensitively with immunosuppressive therapy, we performed a brain biopsy to her, it turned out to be primary CNS (central nervous system) diffuse large B-cell lymphoma (DLBCL). And the morphology, the flow cytometric findings were consistent with germinal center B-like diffuse large B-cell lymphoma. There were only a few case reports concerning primary CNS DLBCL of GCB. The misdiagnose of this patient should alarm the bell, and we should consider biopsy when the lesion is near the cortex in the brain. Why she reacted not sensitively with immunosuppressive therapy later is analyzed.
- Open Access
- 11 June 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 10193
Clinical application of clustered-AChR for the detection of SNMG
Myasthenia gravis (MG) is an autoantibody-mediated disease of the neuromuscular junction (NMJ). However, accumulating evidence has indicated that MG patients whose serum anti-acetylcholine receptor (AChR) antibodies are not detectable (serumnegative MG; SNMG) in routine assays share similar clinical features with anti-AChR antibody-positive MG patients. We hypothesized that SNMG patients would have low-affinity antibodies to AChRs that would not be detectable using traditional methods but that might be detected by binding to AChR on the cell membrane, particularly if they were clustered at the high density observed at the NMJ. We expressed AChR subunits with the clustering protein rapsyn (an AChR-associated protein at the synapse) in human embryonic kidney (HEK) cells and we tested the binding of the antibodies using immunofluorescence. With this approach, AChR antibodies to rapsyn-clustered AChR could be detected in the sera from 45.83% (11/24) of SNMG patients, as confirmed with fluorescence-activated cell sorting (FACS). This was the first application in China of cell-based AChR antibody detection. More importantly, this sensitive (and specific) approach could significantly increase the diagnosis rate of SNMG.
- 11 June 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 10193
Open AccessClinical application of clustered-AChR for the detection of SNMG
Myasthenia gravis (MG) is an autoantibody-mediated disease of the neuromuscular junction (NMJ). However, accumulating evidence has indicated that MG patients whose serum anti-acetylcholine receptor (AChR) antibodies are not detectable (serumnegative MG; SNMG) in routine assays share similar clinical features with anti-AChR antibody-positive MG patients. We hypothesized that SNMG patients would have low-affinity antibodies to AChRs that would not be detectable using traditional methods but that might be detected by binding to AChR on the cell membrane, particularly if they were clustered at the high density observed at the NMJ. We expressed AChR subunits with the clustering protein rapsyn (an AChR-associated protein at the synapse) in human embryonic kidney (HEK) cells and we tested the binding of the antibodies using immunofluorescence. With this approach, AChR antibodies to rapsyn-clustered AChR could be detected in the sera from 45.83% (11/24) of SNMG patients, as confirmed with fluorescence-activated cell sorting (FACS). This was the first application in China of cell-based AChR antibody detection. More importantly, this sensitive (and specific) approach could significantly increase the diagnosis rate of SNMG.